LPCN News and Press, Lipocine Inc. From 10/26/23

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression PR Newswire Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initia...

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference PR Newswire SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today annou...

2023-10-10 07:35:13 ET More on Akero Akero Therapeutics: An Assessment Biggest stock movers today: Hyatt Hotels, PagerDuty and more Cantor starts Akero at buy, bullish on upcoming data for NASH drug Seeking Alpha’s Quant Rating on Akero Therapeutics ...

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire SALT LAKE CITY , Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today annou...

2023-08-17 08:33:44 ET Tremor International ( TRMR ) -24% on Q2 earnings release . KULR Technology ( KULR ) -24% . on proposed stock offering ; Q2 earnings release . Hawaiian Electric Industries ( HE ) -20% on talks with financial restructurin...

2023-08-10 11:04:26 ET Lipocine press release ( NASDAQ: LPCN ): Q2 GAAP EPS of -$0.68 misses by $0.04 . As of June 30, 2023, Lipocine had $25.8 million of unrestricted cash, cash equivalents and marketable investment securities compared to $32.5 million at December ...

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 PR Newswire SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today ...

2023-07-27 13:46:53 ET More on Lipocine Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% Lipocine announces FDA accepted the marketing application for Tla...

2023-07-27 10:07:10 ET Gainers: Carmell Therapeutics ( CTCX ) +44% . Mallinckrodt ( MNK ) +35% . Evolus ( EOLS ) +28% . Lipocine ( LPCN ) +26% . Spok ( SPOK ) +23% . Losers: Mersana Therapeutics ( MRSN ) -77% . ...

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) Fewer hepatic encephalopathy (HE) events of grade >1 in the ...